Research programme: immunoinflammatory and neurodegenerative disorders therapeutics- Pharnext/Galapagos

Drug Profile

Research programme: immunoinflammatory and neurodegenerative disorders therapeutics- Pharnext/Galapagos

Alternative Names: synergistic drug combinations

Latest Information Update: 15 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Galapagos NV; Pharnext
  • Class Immunotherapies
  • Mechanism of Action Immunomodulators; Inflammation mediator modulators; Neurotransmitter modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Immunological disorders; Neurodegenerative disorders

Most Recent Events

  • 09 Mar 2017 Pharnext and Galapagos agree to develop synergistic drug combinations in France for Immunological and Neurodegenerative disorders
  • 09 Mar 2017 Early research in Immunological disorders in France (unspecified route)
  • 09 Mar 2017 Early research in Neurodegenerative disorders (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top